Drug Transporter (DT) Information

General Information of DT
DT ID DTD0266
Gene Name SLC2A8
Protein Name Glucose transporter type 8
Gene ID
29988
UniProt ID
Q9NY64
TCDB ID
2.A.1.1.89
3D Structure

Modelled DT Structure

Method:homology modeling

Template PDB:4LDS_A

Identity:30.732%

Minimized Score:-782.893 kcal/mol

Detail: Structure Info

Synonyms GLUT-8; GLUT8; GLUTX1; Glucose transporter type X1; SLC2A8; Solute carrier family 2, facilitated glucose transporter member 8
DT Family Major Facilitator Superfamily (MFS)
Sugar Porter (SP) Family
Tissue Specificity Highly expressed in testis, but not intesticular carcinoma. Lower amounts present in most other tissues.
Function This insulin-regulated transporter facilitates glucose transport and binds cytochalasin B in a glucose-inhibitable manner. Seems to be a dual-specific sugar transporter as it is inhibitable by fructose.
Endogenous Substrate(s) Glucose
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 4.0)

(α) Tissue Distribution Level of Glucose transporter type 8
Tissue Distribution Level (TD)

(β) Cell Distribution Level of Glucose transporter type 8
Cell Distribution Level (CD)

(γ) Organelle Distribution Level of Glucose transporter type 8
Organelle Distribution Level (Subc)

Regulatory Variability Data of This DT

(β) Post-translational Modification of Glucose transporter type 8
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of Glucose transporter type 8
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of Glucose transporter type 8
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of Glucose transporter type 8
Exogenous Modulation (EGM)

Structural Variability Data of This DT

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

General Variability Data of This DT

(α) Genetic Polymorphisms of Glucose transporter type 8
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of Glucose transporter type 8
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:           1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
2-Deoxyglucose
 Phase 1/2 Drug Info Cancer 2A00-2F9Z [1]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:           1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
L-lactate
5460161
EM Info Identified using GLUT8-attenuated mice [2]

Drug-DT Affinity Assessed by Cell Line

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:         15 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
2-Deoxyglucose Phase 1/2 Drug Info Xenopus oocytes-GLUT8 Km =2000 microM [1]
References
1 Functional Properties and Genomics of Glucose Transporters. Curr Genomics. 2007 Apr; 8(2): 113128.
2 GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts. Int J Cancer. 2017 Nov 15;141(10):2131-2142.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.